Stem Cell Therapy and Treatments — Procedure Guide, Recovery & Risks | MyMedicPlus

Stem cell therapy is a branch of regenerative medicine that uses living stem cells — undifferentiated cells capable of self-renewal and differentiation into specialised cell types — to repair, replace, or regenerate damaged tissues and organs. The field encompasses both well-established, evidence-based treatments with decades of clinical data and emerging experimental therapies under clinical trial evaluation.

The most proven stem cell therapy is haematopoietic stem cell transplantation (HSCT), used for haematological malignancies, bone marrow failure, and inherited blood disorders since the 1960s. Chimeric antigen receptor T-cell (CAR-T) therapy represents the most transformative recent advance — genetically engineering a patient's own T-cells to recognise and kill cancer cells with unprecedented precision. Mesenchymal stem cell (MSC) therapy for graft-versus-host disease, Parkinson's disease, and orthopaedic applications is under active investigation in hundreds of clinical trials globally.

Patients must distinguish between approved, evidence-based treatments at regulated medical institutions and unproven commercial offerings sold by 'stem cell clinics' without regulatory approval or clinical trial evidence. Regulatory bodies (FDA, EMA, TGA) warn against unproven stem cell interventions that may cause serious harm. The field encompasses haematopoietic stem cell transplantation (HSCT), CAR-T therapy, and emerging MSC therapies for conditions including GvHD and orthopaedic applications.

Established stem cell therapies are indicated for haematological malignancies including acute leukaemia, lymphoma, and myeloma, and for bone marrow failure conditions. In these settings, HSCT provides the only curative option for many patients who have relapsed after or failed to respond to conventional chemotherapy.

Specific patient groups who benefit from proven stem cell therapies include: patients with AML or ALL in complete remission with adverse cytogenetics requiring allogeneic transplant; patients with relapsed or refractory B-cell malignancies responsive to CAR-T therapy (axicabtagene ciloleucel for large B-cell lymphoma, tisagenlecleucel for B-ALL); patients with thalassaemia major or sickle cell disease with matched sibling donors; children with severe combined immunodeficiency (SCID) requiring gene therapy or allogeneic HSCT; and patients with multiple myeloma receiving autologous HSCT as consolidation after induction therapy. Eligibility requires comprehensive assessment by a multidisciplinary haematology or oncology team at a specialist transplant centre.

For HSCT, stem cells are collected from peripheral blood (via G-CSF mobilisation and apheresis — a 4–6 hour process), bone marrow harvest under general anaesthesia at the iliac crests, or from umbilical cord blood. High-dose myeloablative conditioning chemotherapy (±total body irradiation) precedes infusion of the stem cell product, destroying residual malignant cells and creating space in the marrow for donor engraftment. Reduced-intensity conditioning extends eligibility to older patients and those with comorbidities.

For CAR-T therapy, leukapheresis collects the patient's own T-cells; these are sent to a manufacturing facility where they are genetically engineered using viral vectors to express chimeric antigen receptors (typically targeting CD19 on B-cells). Manufacturing takes 2–4 weeks. The patient then receives a short course of lymphodepleting chemotherapy (fludarabine and cyclophosphamide) before CAR-T infusion. Cytokine release syndrome (CRS) — a systemic inflammatory response — occurs in the majority of patients within 2–7 days of infusion and is managed with tocilizumab and corticosteroids in specialised settings.

For allogeneic HSCT, donor stem cell sources include peripheral blood (mobilised with G-CSF and collected by apheresis), bone marrow (harvested under general anaesthesia), and umbilical cord blood (banked at birth). Haploidentical transplants (from mismatched family members) using post-transplant cyclophosphamide have markedly expanded donor availability.

HSCT achieves long-term cure in 40–60% of patients with acute leukaemia in first complete remission and over 80% of patients with aplastic anaemia treated with a matched sibling donor. CAR-T cell therapy (axicabtagene ciloleucel, tisagenlecleucel, lisocabtagene maraleucel) achieves complete remission in 70–90% of patients with relapsed/refractory large B-cell lymphoma and B-cell ALL — diseases previously associated with a median survival of months.

For multiple myeloma, autologous HSCT combined with novel agents achieves median progression-free survival of 5–7 years — significantly superior to non-transplant approaches. Sickle cell disease patients who receive allogeneic HSCT from a matched sibling donor achieve event-free survival exceeding 85% in paediatric series, essentially curing the condition. Approved gene therapies (Casgevy for sickle cell disease, Zynteglo for beta-thalassaemia) using autologous modified HSCs now offer cure without the GvHD risks of allogeneic transplant.

HSCT carries significant risks. Allogeneic transplant-related mortality from non-relapse causes (infection, GvHD, organ toxicity) is 10–20% at 1 year. Graft-versus-host disease (GvHD) — where donor immune cells attack host tissues — affects 40–60% of allogeneic recipients in the acute phase and 30–50% as chronic GvHD, causing multi-organ morbidity requiring prolonged immunosuppression.

CAR-T therapy risks include: cytokine release syndrome (CRS), occurring in 70–90% of patients, ranging from mild fever to life-threatening haemodynamic instability requiring intensive care; immune effector cell-associated neurotoxicity syndrome (ICANS), with confusion, tremor, seizures, and cerebral oedema in 20–50%; prolonged cytopaenia and B-cell aplasia requiring immunoglobulin replacement. Access site complications, veno-occlusive disease (VOD/SOS) of the liver from conditioning, and secondary malignancies are additional concerns with HSCT. Transplant-related mortality (TRM) at 1 year is 10–20% for allogeneic HSCT, driven primarily by infection, GvHD, and organ toxicity.

Recovery after HSCT involves 3–6 weeks of inpatient isolation in a positive-pressure HEPA-filtered room during the neutropenic phase (absolute neutrophil count less than 0.5 × 10^9/L), followed by 6–12 months of immune reconstitution requiring prophylactic antibiotics, antifungals, and antivirals. Patients must avoid crowded spaces, live vaccines, raw foods, and soil contact during immune reconstitution.

CAR-T therapy patients require 2–4 weeks of inpatient monitoring at a certified treatment centre after infusion due to CRS and ICANS risk. Neurological monitoring including daily neurological assessments is performed for the first 2 weeks. After discharge, outpatient monitoring continues weekly for 4 weeks. Return to daily activities occurs at 4–8 weeks post-infusion for those without significant complications, though fatigue and variable immunosuppression persist for months. Long-term survivorship care addresses endocrine, cardiac, pulmonary, and neurocognitive late effects.